Printer Friendly

Identification of probiotic strains isolated from human gastrointestinal tract and investigation of their antagonistic, antioxidant and antiproliferative properties.

Introduction

One of the maj or causes of mortality all over the world is oncological diseases regardless of the level of development of healthcare. Despite the advances in modern science and medicine, it is not possible to reduce the morbidity and mortality level. The main instrument in this fight is the prevention and early diagnosis, which can achieve positive results. Studies conducted in many countries have shown a correlation between the development of the pathological process and those or other errors in the diet [1,2]. Probiotics have a positive effect on the health of the host by improving his/her intestinal microbial balance. Probiotic microorganism should be nonpathogenic and nontoxic and resistant to low pH and salts of bile acids, to increase the chances of survival in the gastrointestinal tract. Probiotics are used for the treatment and prevention of a wide variety of diseases, including cancer [3-12]. Most probiotics are members of two genera of bacteria which produce lactic acid, Lactobacillus and Bifidobacterium, as well as Saccharomyces and Enterococcus [6,13-17].

The objective of this research is to identify the most active probiotic strains isolated from the gastrointestinal tract of humans, to create functional food products for the rehabilitation of patients with cancer.

Materials and Methods

Isolation of strains and their antagonistic activity

Samples of microorganisms were isolated from the gastrointestinal tract of 500 healthy and sick with cancer people of various age groups (Russian Federation). Cultivation was carried out under anaerobic and aerobic conditions. Incubations were performed for 24 h at 37[degrees]C in an incubator. After incubation, cultural and morphological properties of microorganisms were determined according to traditional methods, and we count the number of colony forming units (CFU) of each type of colonies and CFU recalculation per 1 g (ml) of the test material. Pure culture was accumulated for identification and further study. Isolation of the microorganisms was carried out on agar SS (Oxoid CM99) and CPSID (BioMerieux 43211), followed by segregation. If necessary, samples were reconstituted in brain, heart broth. Identification of strains was performed using standard biochemical classification methods using API20E, API 20 Ne, API Staphy and API Step (BioMerieux), according to manufacturer's recommendations.

Each of the 23 isolated strains of the normal flora of the gastrointestinal tract of humans was designated: No. 1-Actinomyces meyeri, No. 2-Actinomyces odontolyticus, No. 3-Bacteroides ovatus, No. 4-Bifidobacterium bifidum, No. 5-Bifidobacterium breve, No. 6-Bifidobacterium dentium, No. 7-Clostridium butyricum, No. 8-Clostridium beijerinckii, No. 9-Enterococcus gallinarum, No. 10-Enterococcus faecalis, No. 11-Escherichia coli, No. 12-Eubacterium aerofaciens, No. 13-Eubacterium lentum, No. 14-Lactobacillus spp., No. 15-Leptotrichia buccalis, No. 16-Micrococcus spp., No. 17-Neisseria mucosa, No. 18-Peptostreptococcus asaccharolyticus, No. 19-Sarcina spp., No. 20-Staphylococcus xylosis, No. 21-Staphylococcus cohni, No. 22-Staphylococcus capitis, No. 23-Streptococcus agalactiae

The antagonistic activity of bacteria was determined by perpendicular grooves on the surface of the medium. We streaked the culture of the test strain in Petri dishes and incubated it at 37[degrees]C for 96 h to form a diffusion in agar and inhibitory compounds. Then perpendicularly from the edge of the dish to the stroke of growing culture, streaked exponential culture of the test strain was tucked, lightly touching the stroke bacterium. The dish was incubated at 37[degrees]C for 36 h once again. The presence and degree of the antagonist activity in the test strain were predetermined by the magnitude of the zone of inhibition test strain at the interface with the prime bacterial growth.

The antioxidant properties of microorganisms

Original [beta]-Phycoerythrin solution was prepared by dissolving 1 mg in 5.6 ml of phosphate buffer (0.2 M, pH 7.0). The working solution was prepared by mixing 300 pl of stock solution with 13.4 ml of phosphate buffer immediately before use. A solution of 2,2'-azobis (2-amidinopropane) dihydrochloride (AAPH) was prepared before the test. For this purpose 60 mg of AAPH was weighed and dissolved in 5 ml of phosphate buffer. A solution of 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) was prepared by dissolving 5 mg in 200 ml of 0.2 M phosphate buffer as a stock solution (100 [micro]). For obtaining the working solution, 1 ml of the solution was mixed with 9 ml of a phosphate buffer. The stock solution was stored at 2[degrees]C. Phosphate buffer was prepared by mixing 0.75 M of solutions Na[H.sub.2]P[O.sub.4], and [K.sub.2]HP[O.sub.4]. to 61.6: 38.9 v/v. The mixture was then diluted 1: 9 with distilled water, and the pH adjusted to 7.0. Working solution (0.2 M) was stored at 2[degrees]C.

To each well of the plate, 20 [micro]l of the corresponding sample and 160 [micro]l of working solution with [beta]-phycoerythrin were added. Immediately before measuring, 20 [micro]l of AAPH was added to each well to initiate the reaction. The plate was covered and placed in the analyzer. In the analysis, the ability of compounds to protect phycoerythrin [beta]-oxidation was monitored by the decay curve. Quantitation was achieved by measuring the net protection area in accordance with the curve of [beta]-phycoerythrin decay in the presence of AAPH. To evaluate the antioxidant activity of culture, the aliquots of samples were diluted and control buffer was added to the reaction mixture; the degree of protection from oxidation of [beta]-Phycoerythrin was quantified by measuring the relative fluorescence at 595 NM and at 535 NM for 70-min period:

The ability to absorb the oxygen radicals

= X x K (sample-[S.sub.blank])/([S.sub.trolox] - [S.sub.blank])

Wherein X is sample volume, UL; K is the dilution factor; S represents the area under the curve corresponding to the index; sample is a pattern; and blank is control.

Hemolytic activity and antibiotic resistance

Hemolytic activity was determined by the presence around the colonies of the hemolysis zone after day incubation of the studied cultures crops of microorganisms to 5% in blood nutrient agar at 37[degrees]C for 24 h. The experiment used human blood O (I) Rh+.

Resistance of testing strains to antibiotics was analyzed with a set of disks, soaked with 0.4% (v/v) of different types of antibiotics (cefuroxime, ciprofloxacin, doxycycline, ampicillin, chloramphenicol, oxacillin, tetracycline, kanamycin, penicillin) by the diffusion method [18]. Discs were applied to dense nutrient medium seeded with the culture of test strain, discs with antibiotics were superimposed and cultured overnight at 37[degrees]C. Then we measured the diameter of the zone of inhibition around the discs.

Cell culture

Cancer cells (LBR2-Burkitt lymphoma, DU145-human prostate cancer, MDAMB-231 MCF7-Human breast cancer, HepG2-hepatocellular carcinoma, U-87-brain cancer, PANC-1-human pancreatic cancer) provided by Cancer Center, Karolinska (Sweden) were cultured in RPMI 1640 (PanEco, Russia) with 10% (v/v) of fetal bovine serum (Hyclone Laboratories, Logan, UK), inactivated 56[degrees]C for 30 min, 2 mM L-glutamine, 100 [micro]g/ml penicillin and 100 [micro]g/ml streptomycin sulfate (PanEco, RF). Cells were incubated in a C[0.sub.2]-incubator under 37 (C in 5% C[O.sub.2] for 15 days to be fully differentiated).

Adhesion of cancer cells

Cancer cells were seeded with 1 ml of medium containing 5 * 104-6,5 * 104 cells/well flat-bottomed 96-well microplate (Costar), and reincubated for 24 h before the addition of the test organisms. The obtained cell cultures (20-180 [micro]l of cell suspension) were incubated for 48 h. The control wells were added with 0.9% sodium chloride solution in an adequate amount (20 [micro]l). The number of live cells in each well after the incubation period was determined by the MTT colorimetric method.

Antiproliferation of colon cancer cells

MTT assay

An MTT calorimetric method based on the ability of dehydrogenases of living cells to reduce 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide (MTT) to purple formazan crystals, insoluble in DMSO. Optical absorption of colored solutions of dimethyl sulfoxide was measured on a tablet photometer Multiskan MS (Lab system, Finland) at [lambda] = 540 NM. Cytotoxicity of testing cell cultures was evaluated according to the formula:

% cell cytotoxicity = (1-the optical absorption in the test samples/ the optical absorption in control) X 100

Trypan Blue exclusion assay

The cancer cells ([10.sup.6] cells/1 ml of cell suspension) were added to a 96-well plate. The suspension was incubated at 37 (C for 24 h. cell viability was examined using Trypan Blue exclusion):

% cell viability = (live cell count/total cell count) X 100

Statistical analysis

All experiments were carried out with three replications. Processing data were carried out by standard methods of mathematical statistics. Differences between means are considered significant when the confidence interval is smaller than 5% (p (0.05)).

Results

Characteristics of probiotic strains

The isolated strains from the gastrointestinal tract of healthy humans and patients microorganisms were divided into normal group, conditionally pathogenic and pathogenic microflora, and only the first group showed no pathogenicity. Antimicrobial, antioxidant, hepatoprotective and antitumor properties of these microorganisms (Actinomyces meyeri, Actinomyces odontolyticus, Bacteroides ovatus, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium dentium, Clostridium butyricum, Clostridium beijerinckii, Enterococcus gallinarum, Enterococcus faecalis, Escherichia coli, Eubacterium aerofaciens, Eubacterium lentum, Lactobacillus spp., Leptotrichia buccalis, Micrococcus spp., Neisseria mucosa, Peptostreptococcus asaccharolyticus, Sarcina spp., Staphylococcus xylosis, Staphylococcus cohni, Staphylococcus capitis, Streptococcus agalactiae) have been only subsequently studied, and each of the strains was assigned a number from No.1 to No. 23, respectively.

Maximum antimicrobial activity against considered test strains are characterized by (Table 1) the following samples No. 4, No. 5, No. 14, No. 16 and No. 23; microbial strains: Bifidobacterium bifidum, Bifidobacterium breve, Lactobacillus spp., Micrococcus spp., Streptococcus agalactiae, respectively.

Preliminary isolation, identification and selection of strains of lactobacilli that do not exhibit hemolytic, cytotoxic, catalase, lecithinase, urease, gelatinase, RNA-ase, DNA-ase activity allowed to use them as promising strains to create a functional food for the rehabilitation of cancer patients. This expands the group of selected specimens, samples No. 14/1-Lactobacillus fermentum, No. 14/2-Lactobacillus plantarum, No. 14/3-with Lactobacillus acidophilus, No.14/4-Lactobacillus salivarius.

The isolated strains are characterized by different antibiotic resistance (Table 2).

Discussion

Important properties of probiotic strains in connection with their use in the technology of food products for functional rehabilitation of cancer patients is the antioxidant activity, hepatoprotective and anticancer properties.

From Figure 1, it follows that the cell-free extracts of strains Lactobacillus fermentum, Micrococcus spp. and Lactobacillus plantarum are characterized by highest antioxidant activity. At the same time, the maximum antioxidant activity in intact cells is observed in strains of Bifidobacterium breve, Lactobacillus salivarius and Lactobacillus plantarum.

We examined the hepatoprotective properties of the strains by observing the inhibiting effect of the microorganisms on [beta]-glucuronidase production by E. coli HGU-3 strain. The main pathological conditions wherein there is an increase of serum [beta]-glucuronidase are liver diseases, especially malignant tumors. The data obtained (Figure 2) indicate that pronounced hepatoprotective properties of the isolated strains are characterized by maximum inhibitory ability: Bifidobacterium breve, Lactobacillus salivarius and Lactobacillus acidophilus.

To study the antiproliferative activity of the isolated strains, the MTT test was performed on various human cancer cell lines (Table 3). All the studied strains have antitumor properties in varying degrees for the different types of cancer cells, which are most pronounced at a concentration of 107 CFU/ml. The presented results allow us to distinguish two strains: Lactobacillus plantarum and Lactobacillus acidophilus.

Conclusion

Probiotics have a positive influence on the immune system as the gastrointestinal flora lead in reducing the impact of mutagenic and carcinogenic substances. The study of phenotypic, morphological properties of the isolated microorganisms and their antimicrobial, antioxidant, anticancer and hepatoprotective properties allows us to identify the eight most active strains (Bifidobacterium bifidum, Bifidobacterium breve, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus salivarius, Micrococcus spp., Streptococcus agalactiae) for their use in the creation of functional food products for the rehabilitation of cancer patients. To improve the efficiency in the rehabilitation of patients with a particular type of cancer, the most promising is a compilation of probiotic complexes.

Acknowledgements

Financial support for this research was provided by the Ministry of Education and Science of the Russian Federation and research partner Department of Microbiology, Tumor and Cell Biology, Karolinska Institute (Stockholm, Sweden). The work was performed within the framework of the agreement No. 14.586.21.0002 dated 17.09.2014 (RFMEFI58614X0002).

References

[1.] Issazadeh K, Azizollahi Aliabadi M, Kazemi Darsanaki R, Khoshkholgh Pahlaviani MRM (2012) Antimutagenic activity of olive leaf aqueous extract by AMES test. Advanced Studies in Biology 9: 397-405.

[2.] Rowland IR, Rumney CJ, Coutts JT, Lievense LC (1998) Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Carcinogenesis 19: 281-285.

[3.] Fuller R (1991) Probiotics in human medicine. Gut 32: 439-442.

[4.] Goldin BR, Gorbach SL (2008) Clinical indications for probiotics: an overview. Clinical Infectious Diseases 46: S96-100.

[5.] Kazemi Darsanaki R, Issazadeh K, Khoshkholgh Pahlaviani MRM, Azizollahi Aliabadi M (2012) Antimutagenic activity of Lactobacillus spp. Isolated from fresh vegetables against sodium azide and 2-nitrofluorene. Journal of Pure and Applied Microbiology 6: 1677-1682.

[6.] Burns AJ, Rowland IR (2000) Anti-carcinogenicity of probiotics and prebiotics. Current Issues in Intestinal Microbiology 1: 13-24.

[7.] Commane D, Hughes R, Shortt C, Rowland I (2005) The potential mechanisms involved in the anti-carcinogenic action of probiotics. Mutation Research 591: 276-289.

[8.] Maragkoudakis PA, Zoumpopoulor G, Miaris C, Kalantzopoulos G, Pot B, et al. (2006) Probiotic potential of Lactobacillus strains isolated from dairy products. International Dairy Journal 16: 189-199.

[9.] Moreno D, LeBlanc DA, Matar C, Perdigo'n G (2007) The application of probiotics in cancer. British Journal of Nutrition 98(Suppl 1): 105-110.

[10.] Pennacchia C, Ercolini D, Blaiotta G, Pepe O, Mauriello G, et al. (2004) Selection of Lactobacillus strains from fermented sausages for their potential use as probiotics. Meat Science 67: 309-317.

[11.] Rafter J (2003) Probiotics and colon cancer. Best Practice and Research Clinical Gastroenterology 17: 849-859.

[12.] Saikali J, Picard C, Freitas M, Holt P (2004) Fermented milks, probiotic cultures, and colon cancer. Nutrition and Cancer 49: 14-24.

[13.] Russell DA, Ross RP, Fitzgerald GF, Stanton C (2011) Metabolic activities and probiotic potential of bifidobacteria. International Journal of Food Microbiology 149(1): 88-105.

[14.] Nami Y, Abdullah N, Haghshenas B, Radiah D, Rosli R, et al. (2014) Probiotic potential and biotherapeutic effects of newly isolated vaginal Lactobacillus acidophilus 36YL strain on cancer cells. Anaerobe 28; 29-36.

[15.] Arici M, Bilgin B, Sagdic O, Ozdemir C (2004) Some characteristics of Lactobacillus isolates from infant faeces. Food Microbiology 21: 19-24.

[16.] Gonet-Surowka AK, Strus M, Heczko PB (2007) Influence of Lactobacilli probiotic strains on apoptosis of colon cancer cell lines. International Journal of Antimicrobial Agents 29: 343-344.

[17.] Thirabunyanon M, Boonprasom P, Niamsup P (2009) The probiotic potential of lactic acid bacteria isolated from fermented dairy milks on antiproliferation of colon cancer cells. Biotechnology Letters 31: 571-576.

[18.] Bauer AW, Kirby WMM, Sherris JC, Turck M (1966) Antibiotic susceptibility testing by a standardized single disk method. American Journal of Clinical Pathology 36: 493-496.

A. Prosekov (1,*), I. Milentyeva (1), S. Sukhikh (1), L. Dyshlyuk (1), O. Babich (1), L. Asyakina (1), S. Ivanova (1), M. Shishin (1), L. Matskova (2)

(1) Department of Bionanotechnology, Kemerovo Institute of Food Science and Technology, 47 Stroiteley Boulevard 650056, Kemerovo, Russia (2) Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 1 Solnavagen 17177, Solna, Stockholm, Sweden

* Corresponding author: Prosekov A, Department of Bionanotechnology, Kemerovo Institute of Food Science and Technology, 47 Stroiteley Boulevard 650056, Kemerovo, Russia

Received: Nov 18, 2015; Accepted: Dec 9, 2015; Published: Jan 2, 2016

Table 1: Antimicrobial activity of microbial strains

Strain           The diameter of the growth inhibition
                       zones of test cultures, mm

            B-6954 (-)           B-5651(+)          B-3502 (-)

1        5.6 [+ or -] 0.3    8.7 [+ or -] 0.4    11.6 [+ or -] 0.8
2        15.5 [+ or -] 0.8   12.4 [+ or -] 0.6   8.8 [+ or -] 0.4
3        5.3 [+ or -] 0.3    8.5 [+ or -] 0.4    6.2 [+ or -] 0.3
4        36.5 [+ or -] 1.8   28.9 [+ or -] 1.4   32.0 [+ or -] 1.6
5        28.4 [+ or -] 1.4   30.6 [+ or -] 1.5   33.2 [+ or -] 1.7
6        5.5 [+ or -] 0.3    8.9 [+ or -] 0.4    14.5 [+ or -] 0.7
7        7.7 [+ or -] 0.4    11.5 [+ or -] 0.6   8.0 [+ or -] 0.4
8        10.6 [+ or -] 0.5   12.2 [+ or -] 0.6   8.9 [+ or -] 0.4
9        13.8 [+ or -] 0.7   10.0 [+ or -] 0.5   7.4 [+ or -] 0.4
10       4.8 [+ or -] 0.2    11.6 [+ or -] 0.6   10.3 [+ or -] 0.5
11       7.5 [+ or -] 0.4    12.3 [+ or -] 0.6   13.4 [+ or -] 0.7
12       6.6 [+ or -] 0.3    11.2 [+ or -] 0.6   13.6 [+ or -] 0.7
13       5.5 [+ or -] 0.3    8.9 [+ or -] 0.4    12.4 [+ or -] 0.6
14       24.9 [+ or -] 1.2   38.2 [+ or -] 1.9   32.4 [+ or -] 1.6
15       7.7 [+ or -] 0.4    10.3 [+ or -] 0.5   14.6 [+ or -] 0.7
16       33.9 [+ or -] 1.7   27.8 [+ or -] 1.4   25.2 [+ or -] 1.3
17       13.5 [+ or -] 0.7   18.9 [+ or -] 0.9   14.2 [+ or -] 0.7
18       13.6 [+ or -] 0.7   12.0 [+ or -] 0.6   16.0 [+ or -] 0.8
19       11.8 [+ or -] 0.6   14.5 [+ or -] 0.7   13.9 [+ or -] 0.7
20       9.6 [+ or -] 0.5    11.5 [+ or -] 0.6   12.0 [+ or -] 0.6
21       6.6 [+ or -] 0.3    13.4 [+ or -] 0.7   15.9 [+ or -] 0.8
22       4.6 [+ or -] 0.2    11.2 [+ or -] 0.6   12.5 [+ or -] 0.6
23       34.0 [+ or -] 1.7   27.6 [+ or -] 1.4   29.0 [+ or -] 1.5

Strain   The diameter of the growth inhibition
             zones of test cultures, mm

           ATCC 9027 (-)       B-8404 ( + )

1        12.3 [+ or -] 0.6   7.2 [+ or -] 0.4
2        10.2 [+ or -] 0.5   6.3 [+ or -] 0.4
3        10.1 [+ or -] 0.5   11.8 [+ or -] 0.6
4        29.3 [+ or -] 1.6   30.9 [+ or -] 1.5
5        35.6 [+ or -] 1.8   26.8 [+ or -] 1.3
6        12.0 [+ or -] 0.6   11.4 [+ or -] 0.6
7        14.7 [+ or -] 0.7   15.0 [+ or -] 0.8
8        9.5 [+ or -] 0.5    5.8 [+ or -] 0.3
9        8.5 [+ or -] 0.4    12.2 [+ or -] 0.6
10       6.7 [+ or -] 0.3    8.9 [+ or -] 0.4
11       9.5 [+ or -] 0.5    10.9 [+ or -] 0.5
12       12.5 [+ or -] 0.6   14.6 [+ or -] 0.7
13       13.0 [+ or -] 0.7   12.7 [+ or -] 0.6
14       29.7 [+ or -] 1.5   28.5 [+ or -] 1.4
15       12.3 [+ or -] 0.6   14.0 [+ or -] 0.7
16       36.7 [+ or -] 1.8   35.5 [+ or -] 1.8
17       12.0 [+ or -] 0.6   15.5 [+ or -] 0.8
18       6.9 [+ or -] 0.3    8.7 [+ or -] 0.4
19       15.6 [+ or -] 0.8   13.3 [+ or -] 0.7
20       14.3 [+ or -] 0.7   7.8 [+ or -] 0.4
21       12.2 [+ or -] 0.6   8.7 [+ or -] 0.4
22       13.7 [+ or -] 0.7   14.5 [+ or -] 0.7
23       35.5 [+ or -] 1.8   33.1 [+ or -] 1.7

Strain   The diameter of the growth inhibition
             zones of test cultures, mm

           ATCC 885-653      ATCC 25923 ( + )

1        8.5 [+ or -] 0.4    9.0 [+ or -] 0.5
2        13.4 [+ or -] 0.7   12.0 [+ or -] 0.6
3        6.3 [+ or -] 0.3    7.8 [+ or -] 0.4
4        33.1 [+ or -] 1.7   37.0 [+ or -] 1.9
5        29.0 [+ or -] 1.5   31.1 [+ or -] 1.6
6        10.5 [+ or -] 0.5   9.3 [+ or -] 0.5
7        12.2 [+ or -] 0.6   6.8 [+ or -] 0.3
8        7.9 [+ or -] 0.4    11.0 [+ or -] 0.6
9        10.0 [+ or -] 0.5   11.0 [+ or -] 0.5
10       10.5 [+ or -] 0.5   11.3 [+ or -] 0.6
11       14.7 [+ or -] 0.7   15.0 [+ or -] 0.8
12       15.3 [+ or -] 0.8   8.6 [+ or -] 0.4
13       14.5 [+ or -] 0.7   16.0 [+ or -] 0.8
14       29.6 [+ or -] 1.5   33.5 [+ or -] 1.7
15       11.8 [+ or -] 0.6   11.0 [+ or -] 0.6
16       34.0 [+ or -] 1.7   32.2 [+ or -] 1.6
17       13.4 [+ or -] 0.7   9.6 [+ or -] 0.5
18       9.0 [+ or -] 0.4    11.2 [+ or -] 0.6
19       14.4 [+ or -] 0.7   16.7 [+ or -] 0.8
20       8.4 [+ or -] 0.4    9.2 [+ or -] 0.5
21       9.5 [+ or -] 0.5    10.2 [+ or -] 0.5
22       15.6 [+ or -] 0.8   7.7 [+ or -] 0.4
23       36.5 [+ or -] 1.8   38.4 [+ or -] 1.9

Keys: B-6954 (-) = Escherichia coli, B-5651 (+) = Bacillus
fastidiosus, B-3502 (-) = Pseudomonas fluorescens, ATCC 9027
(-) = Pseudomonas aeruginosa, B-8404 (+) = Leuconostoc
mesenteroides, ATCC 885-653 = Candida albicans, ATCC 25923
(+) = Staphylococcus aureus

Table 2: Antibiotic resistance of strains

Strain                          Antibiotic

                 I                  II                  III

                   Diameter of the inhibition zone, mm

4        23.0 [+ or -] 1.2           0           36.5 [+ or -] 1.8
5                0                   0           3.2 [+ or -] 0.2
14/1     36.6 [+ or -] 1.8           0           33.0 [+ or -] 1.7
14/2             0           35.4 [+ or -] 1.8   14.2 [+ or -] 0.7
14/3             0           15.6 [+ or -] 0.8           0
14/4             0                   0           18.9 [+ or -] 0.9
16       27.8 [+ or -] 1.4           0           25.6 [+ or -] 1.3
23       32.9 [+ or -] 1.6           0                   0

Strain                           Antibiotic

                 IV                   V                  VI

                    Diameter of the inhibition zone, mm

4        33.2 [+ or -] 1.7    30.6 [+ or -] 1.5           0
5        27.5 [+ or -] 1.4    23.4 [+ or -] 1.2   32.2 [+ or -] 1.6
14/1             0                    0           29.9 [+ or -] 1.5
14/2             0            13.4 [+ or -] 0.7   32.0 [+ or -] 1.6
14/3     17.0 [+ or -] 0.9            0           35.6 [+ or -] 1.8
14/4             0                    0           24.5 [+ or -] 1.2
16       23.9 [+ or -] 1.2            0           22.7 [+ or -] 1.1
23       33.0 [+ or -] 1.7    35.7 [+ or -] 1.8           0

Strain                         Antibiotic

                VII                VIII                 IX

                   Diameter of the inhibition zone, mm

4        27.6 [+ or -] 1.4   28.3 [+ or -] 1.4           0
5                0           29.8 [+ or -] 1.5   30.8 [+ or -] 1.5
14/1     24.5 [+ or -] 1.2   32.0 [+ or -] 1.6   25.6 [+ or -] 1.3
14/2     34.6 [+ or -] 1.7   11.9 [+ or -] 0.6   15.6 [+ or -] 0.8
14/3             0           37.0 [+ or -] 1.9   28.5 [+ or -] 1.4
14/4     22.7 [+ or -] 1.1   30.5 [+ or -] 1.5   26.5 [+ or -] 1.3
16               0           33.4 [+ or -] 1.7   35.0 [+ or -] 1.8
23       34.2 [+ or -] 1.7   27.8 [+ or -] 1.4           0

Keys: I = cefuroxime, II = kanamycin, III = penicillin, IV =
ciprofloxacin, V = doxycycline, VI = ampicillin, VII =
tetracycline, VIII = chloramphenicol, IX = oxacillin

Table 3: Anticancer properties of microbial strains

Strain                   The cancer cells

                  LBR 2                    DU 145

                [TEXT NOT REPRODUCIBLE IN ASCII],
                      105/ 107 KOE/m[pi]}, %

4        86.3 [+ or -] 1.2/45.9    90.8 [+ or -] 1.3/52.1
              [+ or -] 0.6              [+ or -] 0.7
5        62.3 [+ or -] 0.9/32.4    73.4 [+ or -] 1.0/38.3
              [+ or -] 0.4              [+ or -] 0.5
14/1     106.2 [+ or -] 1.5/52.1   94.0 [+ or -] 1.3/46.7
              [+ or -] 0.8              [+ or -] 0.6
14/2     53.4 [+ or -] 0.7/25.5    59.0 [+ or -] 0.8/28.7
              [+ or -] 0.4              [+ or -] 0.4
14/3     75.6 [+ or -] 1.0/33.0    68.9 [+ or -] 1.0/23.5
              [+ or -] 0.5              [+ or -] 0.3
14/4     93.2 [+ or -] 1.3/49.8    88.0 [+ or -] 1.2/45.6
              [+ or -] 0.7              [+ or -] 0.6
16       105.6 [+ or -] 1.5/55.3   85.8 [+ or -] 1.2/42.6
              [+ or -] 0.8              [+ or -] 0.6
23       90.2 [+ or -] 1.3/48.9    113.4 [+ or -] 1.6/65.0
              [+ or -] 0.7              [+ or -] 0.9

Strain                   The cancer cells

                MDAMB-231                   MCF7

                [TEXT NOT REPRODUCIBLE IN ASCII],
                     105/ 107 KOE/m[pi]}, %

4        77.5 [+ or -] 1.1/38.7    92.6 [+ or -] 1.3/46.1
              [+ or -] 0.5              [+ or -] 0.6
5        54.3 [+ or -] 0.8/28.9    65.0 [+ or -] 0.9/34.0
              [+ or -] 0.4              [+ or -] 0.5
14/1     68.9 [+ or -] 0.9/32.4    77.1 [+ or -] 1.1/34.6
              [+ or -] 0.4              [+ or -] 0.5
14/2     62.5 [+ or -] 0.9/31.4    60.6 [+ or -] 0.8/29.7
              [+ or -] 0.4              [+ or -] 0.4
14/3     70.2 [+ or -] 1.0/18.7    73.4 [+ or -] 1.0/21.0
              [+ or -] 0.3              [+ or -] 0.3
14/4     75.4 [+ or -] 1.0/38.9    84.2 [+ or -] 1.2/43.2
              [+ or -] 0.5              [+ or -] 0.6
16       80.9 [+ or -] 1.1/38.7    94.5 [+ or -] 1.3/47.8
              [+ or -] 0.5              [+ or -] 0.7
23       95.7 [+ or -] 1.3/56.7    103.7 [+ or -] 1.4/52.4
              [+ or -] 0.8              [+ or -] 0.7

Strain                  The cancer cells

                  HepG2                     U-87

               [TEXT NOT REPRODUCIBLE IN ASCII],
                     105/ 107 KOE/m[pi]}, %

4        112.2 [+ or -] 1.6/57.0   95.0 [+ or -] 1.3/53.8
              [+ or -] 0.8              [+ or -] 0.8
5        62.9 [+ or -] 0.9/31.3    70.5 [+ or -] 1.0/36.7
              [+ or -] 0.4              [+ or -] 0.5
14/1     85.6 [+ or -] 1.2/35.0    87.0 [+ or -] 1.2/44.2
              [+ or -] 0.5              [+ or -] 0.6
14/2     55.2 [+ or -] 0.8/27.5    57.3 [+ or -] 0.8/28.7
              [+ or -] 0.4              [+ or -] 0.4
14/3     61.2 [+ or -] 0.9/15.6    60.5 [+ or -] 0.8/19.8
              [+ or -] 0.2              [+ or -] 0.3
14/4     80.3 [+ or -] 1.1/42.0    77.3 [+ or -] 1.1/35.6
              [+ or -] 0.6              [+ or -] 0.5
16       79.8 [+ or -] 1.1/39.9    87.3 [+ or -] 1.2/44.5
              [+ or -] 0.6              [+ or -] 0.6
23       88.4 [+ or -] 1.2/45.6    96.7 [+ or -] 1.3/48.9
              [+ or -] 0.6              [+ or -] 0.7

Strain          The cancer cells

                 PANC-1

         [TEXT NOT REPRODUCIBLE IN ASCII],
              105/ 107 KOE/m[pi]}, %

4        84.3 [+ or -] 1.2/37.2
              [+ or -] 0.5
5        58.9 [+ or -] 0.8/29.6
              [+ or -] 0.4
14/1     92.2 [+ or -] 1.3/48.9
              [+ or -] 0.7
14/2     64.2 [+ or -] 0.9/32.1
              [+ or -] 0.4
14/3     58.9 [+ or -] 0.8/23.4
              [+ or -] 0.3
14/4     72.1 [+ or -] 1.0/36.9
              [+ or -] 0.5
16       89.5 [+ or -] 1.2/46.7
              [+ or -] 0.7
23       79.0 [+ or -] 1.1/43.4
              [+ or -] 0.6
COPYRIGHT 2015 HATASO Enterprises, LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article: Open Access
Author:Prosekov, A.; Milentyeva, I.; Sukhikh, S.; Dyshlyuk, L.; Babich, O.; Asyakina, L.; Ivanova, S.; Shis
Publication:Biology and Medicine
Article Type:Report
Date:Dec 1, 2015
Words:4564
Previous Article:Distinctive features of systolic function of the left ventricle in patients with chronic obstructive lung disease in extremely cold climate...
Next Article:C3 glomerulonephritis and plasma cell dyscrasia: expanding the etiologic spectrum.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters